Share

Merck & Co., Inc. (MRK.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 14 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 20 September 2026Deep analysis 20 September 2026

Publisher

Russlan Ramdowar

25 min readAudit All Past Forecasts

14 AI Advisor Reports

Select an advisor report.

SynthesizerCombines all advisor views

Synthesis of 14 independent opinions

Diversity of ModelsSame approach, varied models

Diversity of FrameworksDifferent investing styles

AI Researcher

Opus 5

Universal Investor AI

The Polymath Framework

Model rating

Neutral

5-Year Return Est.

+16.3%

Includes 1.60% annual net dividend contribution

1. Investment Thesis — Base Case

The central tension is simple and uncomfortable: Merck has bought a credible bridge across the 2028 cliff, but investors have already paid for the crossing. The 2026 re-rating from roughly 9x to 17x forward happened on flat underlying earnings, financed by defensive rotation under a tightening Fed rather than by improved fundamentals. The base case therefore projects a stock that drifts lower into the February 2027 CMS decision, grinds sideways through the pre-cliff years, troughs in early 2029 as the first post-biosimilar guidance lands, then recovers as Lipfendra, Winrevair, Ohtuvayre and the acquired pipeline rebuild the base. Total five-year price appreciation is modest; the dividend does most of the work.

Underlying 2026 EPS near $8.60 after adding back $5.93 of Terns and Cidara charges [3][4].
At $147 that is roughly 17x, versus about 9x forward eleven months earlier at $86 [5].
A $363bn market cap plus roughly $50bn net debt implies about 15x normalised EBITDA near $27bn [6].

Historical prices and published forecast

Observed price
Published advisor forecast

Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.

View chart values

Historical prices and published forecast — published chart values
Series	Date	Value (USD)
Observed price	2021-09-16	71.9
Observed price	2021-10-09	80.3
Observed price	2021-10-15	78.5
Observed price	2021-11-01	88.6
Observed price	2021-11-13	83.8
Observed price	2021-12-06	72.5
Observed price	2021-12-12	73.3
Observed price	2022-01-04	78.7
Observed price	2022-01-15	81.6
Observed price	2022-02-02	79.2
Observed price	2022-02-25	76.3
Observed price	2022-03-03	77.6
Observed price	2022-03-09	77.9
Observed price	2022-04-01	83.6
Observed price	2022-04-06	86.8
Observed price	2022-04-24	85.0
Observed price	2022-05-05	88.4
Observed price	2022-05-23	94.3
Observed price	2022-06-15	85.1
Observed price	2022-06-26	92.3
Observed price	2022-07-08	93.3
Observed price	2022-07-25	90.0
Observed price	2022-07-31	88.5
Observed price	2022-08-18	91.7
Observed price	2022-09-04	86.3
Observed price	2022-09-21	86.7
Observed price	2022-09-27	86.7
Observed price	2022-10-20	95.6
Observed price	2022-10-26	99.4
Observed price	2022-11-18	105
Observed price	2022-11-24	107
Observed price	2022-12-11	111
Observed price	2023-01-03	114
Observed price	2023-01-15	111
Observed price	2023-01-21	109
Observed price	2023-02-07	106
Observed price	2023-03-08	110
Observed price	2023-03-14	105
Observed price	2023-03-20	104
Observed price	2023-04-12	113
Observed price	2023-04-18	115
Observed price	2023-05-05	118
Observed price	2023-05-17	116
Observed price	2023-06-09	109
Observed price	2023-06-26	113
Observed price	2023-07-08	109
Observed price	2023-07-25	107
Observed price	2023-08-06	105
Observed price	2023-08-11	107
Observed price	2023-09-03	110
Observed price	2023-09-09	109
Observed price	2023-10-02	103
Observed price	2023-10-08	104
Observed price	2023-10-20	102
Observed price	2023-11-06	103
Observed price	2023-11-23	101
Observed price	2023-12-05	105
Observed price	2023-12-28	110
Observed price	2024-01-03	115
Observed price	2024-01-26	121
Observed price	2024-02-12	125
Observed price	2024-02-24	128
Observed price	2024-03-01	127
Observed price	2024-03-18	122
Observed price	2024-03-30	130
Observed price	2024-04-16	125
Observed price	2024-05-04	128
Observed price	2024-05-15	132
Observed price	2024-05-27	127
Observed price	2024-06-07	131
Observed price	2024-06-25	131
Observed price	2024-07-18	126
Observed price	2024-07-24	126
Observed price	2024-08-04	112
Observed price	2024-08-27	117
Observed price	2024-09-08	115
Observed price	2024-09-19	117
Observed price	2024-10-07	109
Observed price	2024-10-18	108
Observed price	2024-11-10	101
Observed price	2024-11-16	97.3
Observed price	2024-11-28	103
Observed price	2024-12-15	100
Observed price	2024-12-21	98.4
Observed price	2025-01-13	100
Observed price	2025-02-05	89.5
Observed price	2025-02-11	85.1
Observed price	2025-03-06	93.6
Observed price	2025-03-12	94.7
Observed price	2025-04-04	83.2
Observed price	2025-04-16	78.8
Observed price	2025-04-27	83.0
Observed price	2025-05-09	78.1
Observed price	2025-05-15	76.8
Observed price	2025-06-07	78.7
Observed price	2025-06-13	81.7
Observed price	2025-07-06	80.7
Observed price	2025-07-23	83.8
Observed price	2025-08-04	79.9
Observed price	2025-08-27	85.1
Observed price	2025-09-02	85.5
Observed price	2025-09-25	80.5
Observed price	2025-10-01	84.8
Observed price	2025-10-06	88.2
Observed price	2025-11-04	84.1
Observed price	2025-11-22	101
Observed price	2025-11-27	104
Observed price	2025-12-09	99.4
Observed price	2025-12-26	106
Observed price	2026-01-18	109
Observed price	2026-01-24	108
Observed price	2026-02-16	121
Observed price	2026-02-22	123
Observed price	2026-03-17	115
Observed price	2026-04-09	121
Observed price	2026-04-15	116
Observed price	2026-04-27	110
Observed price	2026-05-14	113
Observed price	2026-05-20	114
Observed price	2026-05-26	119
Observed price	2026-06-18	115
Observed price	2026-06-30	129
Observed price	2026-07-17	127
Observed price	2026-07-23	131
Observed price	2026-08-15	136
Observed price	2026-08-21	152
Observed price	2026-09-13	145
Observed price	2026-09-22	151
Observed price	2026-09-25	149
Published advisor forecast	2026-09-18	147
Published advisor forecast	2026-12-18	142
Published advisor forecast	2027-03-18	135
Published advisor forecast	2027-06-18	139
Published advisor forecast	2027-09-18	144
Published advisor forecast	2027-12-18	141
Published advisor forecast	2028-03-18	136
Published advisor forecast	2028-06-18	139
Published advisor forecast	2028-09-18	134
Published advisor forecast	2028-12-18	130
Published advisor forecast	2029-03-18	124
Published advisor forecast	2029-06-18	126
Published advisor forecast	2029-09-18	128
Published advisor forecast	2029-12-18	132
Published advisor forecast	2030-03-18	136
Published advisor forecast	2030-06-18	139
Published advisor forecast	2030-09-18	143
Published advisor forecast	2030-12-18	146
Published advisor forecast	2031-03-18	150
Published advisor forecast	2031-06-18	153
Published advisor forecast	2031-09-18	158

2. Scenarios & Signals

Bull case

The bull case activates if CMS softens the subcutaneous rule and Qlex conversion runs past half the franchise before December 2028. Retained oncology revenue then funds an uninterrupted buyback, the 2029 earnings trough never materialises, and Lipfendra plus Winrevair push non-Keytruda revenue through $25bn. At that point the market stops applying a cliff discount and re-rates Merck as a diversified compounder, making today's 17x look like the entry multiple rather than the exit multiple.

Bear case

The bear case activates when the February 2027 CMS list confirms subcutaneous inclusion and biosimilar erosion then exceeds 60% of US Keytruda within eighteen months. Guidance resets, the buyback is curtailed to protect a stretched balance sheet carrying roughly $50bn of , and the defensive rotation premium unwinds simultaneously as disinflation returns capital to growth. Flat earnings at 17x become falling earnings at 12x — a compounding repricing, not a single derating, and a multi-year drawdown for holders.

Current crowd narrative

The settled belief is that the Keytruda cliff is fully discounted and that 2026's dealmaking bought the bridge. Twenty-eight analysts average $152.96 with a Buy consensus; Wells Fargo moved to $170 [17]. The anchoring error is the October 2025 price of $86 — anything above it feels like vindicated value, disguising the fact that flat earnings now carry a 17x multiple [5].

Alpha-gap assessment

The crowd overestimates these shares modestly. The decisive overlooked evidence is that the entire 2026 move is multiple expansion, not earnings: strip out $5.93 of Terns and Cidara charges and 2026 underlying is roughly $8.60 against $8.98 in 2025 [3][4]. Investors are paying 17x a flat, pre-cliff earnings stream whose largest component faces biosimilars in December 2028 [9], while consensus revenue growth of 2.8% annually lags the industry's 9.1% [19]. The valuation assumes a bridge that is real but not yet load-bearing.

Convergence catalyst

The CMS selected-drug list due by February 1, 2027 is the trigger [9]. Including subcutaneous Keytruda removes the evergreening defense and forces analysts to rebuild 2029-2030 models on negotiated pricing. The first observable sign of repricing will be sell-side franchise forecasts cut before the rule is even finalised.

Macro-regime alignment

The wind is currently at its back for the wrong reason: a 3.75%-4.00% policy rate, 3.4% inflation and an energy shock have pushed capital into inelastic, cash-generative defensives, lifting Merck's multiple without any earnings improvement. That support is a dependency, not a moat. If disinflation restores appetite for cyclical and AI-levered growth, the rotation premium unwinds before the cliff even arrives.

Paywalled preview begins: Macro-regime alignment

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Sentiment and regime

Greed and fear sentiment: 0.3
Expected volatility regime: moderate
Convergence-cycle position: momentum

Primary drivers

Primary drivers supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Qlex: THE Franchise Escape Hatch	Keytruda Qlex is the designed escape hatch: subcutaneous dosing shifts patients onto a formulation whose protection extends past the December 2028 IV biosimilar wave [9]. Qlex reached $463m inside an $8.4bn combined franchise quarter, roughly 5.5% conversion after two quarters of launch [1]. Every incremental conversion point preserves several hundred million dollars of high-margin US revenue, directly defending the earnings base investors are currently capitalising.	Not available	+18.0%
Lipfendra Opens A Primary CARE LANE	FDA approval of LIPFENDRA, the first once-daily oral PCSK9 inhibitor cutting LDL-C by 56-59% placebo-adjusted, hands Merck a primary-care-scale cardiometabolic market it has lacked since Zetia [12][13]. Alongside Winrevair's 75% Q2 growth and Animal Health's 8%, the non-oncology base already compounds independently [1]. These launches convert pipeline optionality into reported revenue exactly as oncology concentration becomes the bear case.	Not available	+14.0%
Defensive CASH FLOW IN A Tightening WORL	With the Fed at 3.75%-4.00%, ten-year yields near 5.0% and Brent above $100, investors have paid up for inelastic, dollar-denominated cash flows insulated from the energy shock. Merck produced $12.4bn of FY2025 free cash flow on 36.2% operating margins, and oncology demand does not flex with industrial activity. This rotation explains much of the move from roughly 9x forward in October 2025 to 17x today [5].	Not available	+10.0%
Buying THE Bridge Expensing IT NOW	Merck deployed roughly $26bn in twelve months — Verona $10bn, Cidara $9.2bn, Terns $6.7bn — purchasing late-stage assets rather than waiting on internal discovery [8][16]. Because those were expensed as acquired IPR&D rather than capitalised, reported profit absorbed $14.7bn up front while revenue arrives later, mechanically flattering future comparisons [1]. Combined with a roughly $3bn annual repurchase, pain is front-loaded and accretion back-loaded.	Not available	+9.0%

Primary frictions

Primary frictions supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
December 2028: HALF THE Revenue Unbolts	Keytruda booked $31.7bn in 2025, close to half of group revenue, and Leerink expects biosimilar entry in December 2028 [7][9]. Analogue erosion for a large intravenous oncology biologic runs 40-60% of US sales within two years, implying roughly $10-14bn of near-group-margin revenue evaporating across 2029-2031. Nothing in the launch portfolio replaces that scale inside this forecast horizon; the drag is arithmetic, not sentiment.	Not available	-26.0%
A Multiple Earned BY Rotation NOT Growt	The decisive fact is that underlying earnings did not move. Adding back $5.93 of Terns and Cidara charges gives roughly $8.60 of 2026 non-GAAP EPS against $8.98 in 2025 [3][4], yet the stock re-rated from about 9x forward at $86 to roughly 17x at $147 [5]. Multiples granted by defensive rotation mean-revert once the rotation stops or cliff arithmetic reasserts itself.	Not available	-18.0%
CMS Closes THE Evergreening DOOR	The June 2026 CMS proposed rule would sweep subcutaneous Keytruda into Medicare negotiation alongside its intravenous parent, deliberately closing the evergreening route and blunting the primary defense [9][10]. Qlex is priced identically to IV Keytruda, so formulation switching offers no pricing cushion [11]. The selected-drug list is due by February 1, 2027 — a dated, near-binary repricing event landing inside the first two forecast quarters.	Not available	-12.0%
CASH FLOW THAT IS NOT Really There	Headline TTM free cash flow of $16.1bn excludes roughly $14.7bn of acquisition cash routed through R&D, so genuine post-business-development free cash was materially negative in H1 2026 [1]. Estimated net debt has climbed toward $50bn against $52.6bn of end-2025 equity, and Davis remains open to further $15bn transactions [6][16]. Distributable capacity and buyback flexibility are thinner than the screen implies.	Not available	-8.0%

Tail opportunities

Tail opportunities supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
QLEX Converts FAST CMS Blinks	Two conditions combining would halve the cliff: the final CMS rule softens or delays subcutaneous inclusion after industry comment, and Qlex conversion accelerates past 50-60% of US franchise volume by late 2028 rather than the ~5.5% run-rate visible in Q2 2026 [1][9]. Merck would retain perhaps $8-10bn of revenue the market has already written off, and the 2029 earnings trough would be shallow rather than severe. It stays below 50% because CMS explicitly framed the rule as anti-evergreening, and community oncology switching historically lags.	25.0%	+30.0%
Three Launches Become ONE Franchise	Sac-TMT in solid tumours, tulisokibart in ulcerative colitis and the once-weekly oral islatravir/lenacapavir HIV regimen with Gilead each reach registrational success and scale together during 2028-2030 [15]. Combined peak potential of $10bn-plus would validate management's mid-2030s new-product ambition and convert Merck's narrative from melting franchise to diversified compounder, justifying a durable 17-18x rather than a cliff-discounted 13x. Probability stays under half because Phase 3 attrition, payer pushback on immunology pricing and launch-execution risk each independently break the chain.	30.0%	+22.0%

Tail risks

Tail risks supplied in this advisor's published forecast
Force	Rationale	Probability	Expected price impact
Erosion PLUS MOST Favoured Nation Pricing	Faster-than-modelled biosimilar erosion from late 2028 collides with a US most-favoured-nation drug-pricing regime layered onto the 2026 tariff and Section 301 reset. If US Keytruda loses 60%-plus within eighteen months while list-price reference cuts compress international revenue, the 2029 guide could imply EPS near $6 rather than $8, and a cliff-era multiple of 11-12x applies to that lower base. Probability sits below half because MFN implementation has repeatedly stalled legally and subcutaneous retention provides partial insulation.	33.0%	-28.0%
THE $40bn Empire Building DEAL	Management, having spent roughly $26bn in a year and signalled appetite for further $15bn transactions [16], responds to a pipeline setback by attempting a transformational acquisition financed with debt and equity. Net debt would exceed $70bn against a shrinking Keytruda cash engine, buybacks would halt, and investors would reprice Merck as a serial acquirer rather than a disciplined allocator. It remains below 50% because the board has favoured bolt-on cash deals and credit rating protection to date.	24.0%	-19.0%

Step-by-step forecast path

Universal Investor forecast path for prediction task predrqst_batch_task__xrefsubjtskconf_bf1dba9f-1198-5f9b-80c6-f953ea29067c__sb7__20260920064920277661
Step	Forecast date	Step change	Projected value (USD)	Scenario rationale
1	December 18, 2026	-3.0%	142.46	October 29 results face the company-flagged Ohtuvayre stocking unwind and another quarter of acquisition-charge noise obscuring clean earnings. With ten-year yields near 5%, a freshly minted 17x defensive multiple gives back ground into year-end.
2	March 18, 2027	-5.0%	135.34	CMS publishes the IPAY 2029 selected-drug list by February 1. Inclusion of subcutaneous Keytruda alongside the intravenous parent removes the evergreening defense, forcing sell-side analysts to cut 2029-2030 franchise revenue assumptions immediately.
3	June 18, 2027	+3.0%	139.40	Relief follows as Q1 reporting shows Qlex conversion accelerating beyond ten percent of franchise volume and Lipfendra prescriptions building steadily. Charge-free earnings finally restore a credible, comparable EPS base for valuation work.
4	September 18, 2027	+3.0%	143.58	Mid-year pipeline readouts including sac-TMT registrational data and tulisokibart filings support sentiment, while continued repurchases shrink the share count. Cooling inflation firms easing expectations, modestly lowering the discount rate applied to pharmaceutical cash flows.
5	December 18, 2027	-2.0%	140.71	Initial 2028 guidance framing arrives with biosimilar entry now roughly twelve months away. Management's replacement-revenue bridge invites forensic scrutiny, and institutional investors begin trimming ahead of the cliff rather than waiting for it.
6	March 18, 2028	-3.0%	136.49	Pre-cliff de-risking intensifies as biosimilar manufacturers confirm December launch readiness. Positioning rotates toward pharmaceutical names with later patent horizons, compressing Merck's relative multiple despite unchanged near-term earnings delivery and intact guidance.
7	June 18, 2028	+2.0%	139.22	A strong final pre-cliff year unfolds: Keytruda still compounding, Lipfendra approaching blockbuster run-rate, Winrevair scaling further. Beat-and-raise mechanics briefly outweigh the countdown, producing a modest bounce from technically oversold levels.
8	September 18, 2028	-4.0%	133.65	The last quarter before biosimilar entry. Management withholds or heavily caveats 2029 guidance, and the market prices erosion at the harsher end of the historical analogue range, compressing the multiple further.
9	December 18, 2028	-3.0%	129.64	Keytruda intravenous biosimilars launch in the United States during December. Early discounting and payer switching decisions confirm the erosion pace, and subcutaneous retention becomes the only variable investors will discuss.
10	March 18, 2029	-4.0%	124.46	The 2029 guide lands: double-digit oncology revenue decline, dividend maintained but repurchases curtailed to protect leverage. Trough earnings expectations reset sharply lower, and the shares establish their cycle low here.
11	June 18, 2029	+1.0%	125.70	Erosion tracks marginally better than the bear case as subcutaneous dosing holds share in community oncology settings. This is stabilisation rather than recovery; the earnings base stops falling while the multiple stays depressed.
12	September 18, 2029	+2.0%	128.21	New-product revenue from Lipfendra, Winrevair, Ohtuvayre and Capvaxive crosses a visible threshold in the sales mix. Investors begin modelling the post-Keytruda earnings base rather than extrapolating the oncology decline rate.
13	December 18, 2029	+3.0%	132.06	Guidance for 2030 implies the earnings trough has passed. Cost-programme savings and lower amortisation lift margins, while a covered dividend yield attracts income buyers at a genuinely depressed valuation multiple.
14	March 18, 2030	+3.0%	136.02	Full-year results confirm growth resumption excluding Keytruda, with cost savings landing as promised. Deleveraging after the 2025-2026 deal spree restores buyback capacity, so per-share economics improve faster than reported revenue.
15	June 18, 2030	+2.0%	138.74	A steady quarter. Assets acquired through Cidara and Terns enter late-stage readouts, delivering incremental progress rather than discrete catalysts, so the shares track a broad, rate-sensitive defensive equity market.
16	September 18, 2030	+3.0%	142.91	Mid-2030s revenue ambitions gain credibility as new franchises scale toward critical mass. The multiple re-expands modestly from cliff-trough levels as the market reprices Merck from melting franchise toward diversified compounder.
17	December 18, 2030	+2.0%	145.76	Year-end positioning favours healthcare as policy rates normalise lower. Merck's rebuilt portfolio supports mid-single-digit growth guidance for 2031, driving gradual appreciation without any return to the multiple excess of 2026.
18	March 18, 2031	+3.0%	150.14	Results confirm that the replacement portfolio now carries the group. Animal Health and vaccines supply earnings stability, while recovering free cash flow funds a re-accelerated share repurchase programme and dividend growth.
19	June 18, 2031	+2.0%	153.14	Incremental gains accrue from label expansions and the once-weekly oral HIV regimen partnered with Gilead. Growth is real but unspectacular, so the shares compound alongside earnings rather than re-rating upward again.
20	September 18, 2031	+3.0%	157.73	Horizon close: Merck exits as a mid-single-digit grower with a rebuilt, less concentrated pipeline. Valuation settles near sixteen times recovered earnings, delivering modest price appreciation plus a comfortably covered dividend.

Advisor and configuration

Advisor: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release
Persona: Universal Investor
Archetype: The Polymath
Model: 2026-07-24 release
Provider: Anthropic
Mode: RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity
Task configuration: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release__equity__json__extnd_invest_thesis_4q_alphassym__ts_num_desc__h5y_s3m__var1__researcher__standard_creativity_high_thinking__batch
Forecast horizon: 5 year
Forecast steps: 20 steps of 3 month
Assembly type: Balanced Assembly
Assembly name: universal_investor__the_polymath__anthropic_claude_opus_5__20260724_release RESEARCHER Forecast Assembly
Input format: inmemory_base_placeholders__latest_eod_close_price_with_stats_and_fundamentals__var1
Output format: Equity Extended Investment Thesis (4 Quadrants and Alpha Asymmetry) + Pct Change Timeseries for Close Price with Rationale, (5Y Quarterly)

Read the complete Universal Investor advisor methodology

Configuration components

aiassmprmtcmpnt_b995bbe2-6a15-55be-a576-525904f696e8
aiassmprmtcmpnt_c55d1851-d218-5d30-b83b-54bbda31e2ee
aiassmprmtcmpnt_930157b1-05d7-5699-bf0a-738645ee42fd
aiassmprmtcmpnt_3c0c459a-0d4a-50ca-87df-c172ec5618aa
aiassmprmtcmpnt_8115cc2a-d418-54b1-a616-49dfa91195f4

Research sources

[1]Merck & Co., Inc. - Form 10-Q - FY2026sec.gov
[2]Merck (MRK) Q2 2026 Earnings Call Transcript - The Globe and Mailtheglobeandmail.com
[3]Merck (MRK) earnings Q2 2026cnbc.com
[4]Merck & Co., Inc. - Form 8-K - FY2026sec.gov
[5]Merck (MRK) Stock Price Prediction: 2025, 2026, 2030benzinga.com
[6]Merck: Aggressive M&A Efforts To Prepare For A Keytruda Patent Cliff (NYSE:MRK) | Seeking Alphaseekingalpha.com
[7]Merck (MRK) Stock Sees Modest Fair Value Lift As Analysts Raise Targetsfinance.yahoo.com
[8]Merck to buy Terns Pharmaceuticals for $6.7 billion to boost cancer pipelinecnbc.com
[9]Medicare drug price rule may target under-the-skin Keytruda and Opdivo | BioPharma Divebiopharmadive.com
[10]Medicare drug price rule may target under-the-skin cancer immunotherapies | Healthcare Divehealthcaredive.com
[11]How Much Does Keytruda Cost in 2026? List Price, Insurance, Medicare & Medicaidrefillrelay.com
[12]Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia - Merck.commerck.com
[13]Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs - MedCity Newsmedcitynews.com
[14]Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipelinebusinesswire.com
[15]Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2026 Financial Results; Highlights Key Regulatory and Clinical Milestones Across Broad, Diverse Pipeline - BioSpacebiospace.com
[16]Merck to buy Cidara Therapeutics for $9.2 billion as Keytruda patent cliff approachesinvezz.com
[17]Merck & Co. (MRK) Stock Price & Overviewstockanalysis.com
[18]MRK Stock Quote Price and Forecast | CNNcnn.com
[19]Merck (NYSE:MRK) - Stock Analysis - Simply Wall Stsimplywall.st
[20]Mercks & Co's sprint against the KEYTRUDA patent cliff: will it cross the finish line?kletthamerinsights.com
[21]Merck 2026 Outlook: Keytruda Patent Cliff, Pipeline Strategy & Competitive Intelligence | SyneticXsyneticx.com
[22]Keytruda Cost 2026: Price Per Dose, Medicare Coverage & $25 Copay Programuntravel.info
[23]How Much Does Keytruda Cost with Insurance in the U.S. (2026 Update) | Real Prices, Coverage & Savings Tipsuntravel.info

Back to advisor navigation

End of the paywalled preview

The excerpt from Macro-regime alignment to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Other AI Advisor reports — limited previews

Niccolo Machiavelli — RESEARCHER (Web Search Enabled) with High Reasoning and Standard Creativity

Gemini 3.8 Flash

Limited structural preview, provided as simplified HTML. The complete report contains substantially more research: its investment thesis; bull and bear scenarios; macro-regime analysis; drivers, risks and opportunities; quarterly forecast tables and rationale; references and published configuration. Those findings and datasets are not included here. Sign in with the required subscription to open this advisor's full report.